The Times Australia
News From Asia

.
The Times Real Estate

.

CK Life Sciences Presenting Preclinical Data for Its Investigational Dual-Antigen Cancer Vaccines, Co-targeting PRAME and PD-L1, at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

HONG KONG SAR - Media OutReach - 1 November 2023 - CK Life Sciences Int'l., (Holdings) Inc. is presenting preclinical data for its investigational dual-antigen cancer vaccines, co-targeting PRAME (preferentially expressed antigen in melanoma) and PD-L1 (programmed death-ligand 1), on November 4 at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California, USA.



The investigational cancer vaccines evaluated in the preclinical study contain antigenic sequences of PRAME and PD-L1 intended to induce anti-cancer immune responses. PRAME is a cancer antigen highly expressed in many different types of cancers and has been associated with different oncogenic processes. PD-L1 represents one of the most important immune checkpoint antigens highly expressed on cancer cells to limit T-cell activation in the tumour microenvironment.

"CK Life Sciences has a growing pipeline of cancer vaccines in various stages of development. The preclinical efficacy results of our dual-targeting PRAME/ PD-L1 cancer vaccines in liver cancer are promising and we hope to start clinical trials in the coming years," said Melvin Toh, Vice President & Chief Scientific Officer at CK Life Sciences. "Liver cancer is the second most common cause of cancer death in Asia and remains a major unmet medical need. We plan to investigate the PRAME/ PD-L1 dual-targeting cancer vaccines further in liver cancer and other cancer types known to over-express PRAME and PD-L1."

DETAILS ON POSTER PRESENTATION:

  • Abstract 1336: Cancer vaccine co-targeting PRAME and PD-L1 exerts significant tumour growth inhibition in syngeneic mouse hepatocellular carcinoma models
  • Authors: Kin-Tak Chan, Chen-Yi Chiang, Chai Ho, Melvin Toh, Hsin-Wei Chen
  • Session Date and Time: Saturday, November 4th from 9:00 a.m. - 8:30 p.m. Pacific Standard Time

In this preclinical study, we investigated whether dual-antigen cancer vaccines co-targeting PRAME and PD-L1 could suppress tumour growth in both prophylactic and therapeutic syngeneic mouse hepatocellular carcinoma (HCC) models.

Two recombinant fusion protein vaccines comprised of PD-L1 and PRAME with or without GM-CSF were synthesised and formulated with a Toll-like receptor 9 agonist CpG oligodeoxynucleotide and aluminum hydroxide for vaccination. In the prophylactic tumour model study, the vaccines were administrated subcutaneously twice at a two-week interval before implantation of mouse HCC cells expressing PRAME, followed by weekly vaccination. In the therapeutic model study, the vaccines were administrated weekly into the animals after tumour cell implantation. Body weight and tumour volume were measured three times a week.

All mice experienced a recoverable body weight loss without any abnormal behavior or reduction of activity after vaccination. In the prophylactic model (n=10 mice), both fusion protein vaccines significantly inhibited tumour growth, with 76.4% (P) and 59.5% (P) tumour growth inhibition (TGI) compared to control group, respectively. Importantly, there were some vaccinated mice without palpable tumour mass at the end of the study. These results were consistent with that found in the therapeutic model study (n = 10 mice), in which both vaccines significantly inhibited tumour growth, with 43.4% (P) and 40.7% (P) TGI, respectively, and prolonged animal survival compared to the control group (P.

The results of this preclinical study clearly highlight the potential of simultaneously targeting PRAME and PD-L1 by fusion protein vaccination in cancer immunotherapy.

DISCLAIMER

This press release may contain forward-looking statements regarding the Group's research and development projects which may involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements.

All information in this press release is for general reference only and is not intended as investment advice or medical advice. CK Life Sciences Int'l., (Holdings) Inc. does not warrant or represent, express or implied, as to the accuracy, completeness or updated status of such information. No liability will be accepted for any loss or damage howsoever arising from or in reliance upon such information.

REFERENCES

[1] Gradecki S, Slingluff C, Gru A. J Cutan Pathol. PRAME expression in 155 cases of metastatic melanoma.

Accessed at https://onlinelibrary.wiley.com/doi/10.1111/cup.13876.

[2] Oyama K, Kanki K, Shimizu H, Kono Y, Azumi J, Toriguchi K, Hatano E, Shiota G. Gastrointest Tumors. Impact of preferentially expressed antigen of melanoma on the prognosis of hepatocellular carcinoma.

Accessed at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465675/.

[3] Thongprasert S, Yang PC, Lee J, Soo R, Gruselle O, Myo A, Louahed J, Lehmann F, Brichard V, Coche T. Lung Cancer. The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.

Accessed at https://pubmed.ncbi.nlm.nih.gov/27794402/.

[4] Epping M, Hart A, Glas A, Krijgsman O, Bernards R. Br J Cancer. PRAME expression and clinical outcome of breast cancer.

Accessed at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527791/.

[5] Ahmad S, Borch T, Hansen M, Andersen M. Cancer Immunol Immunother. PD-L1-specific T cells.

Accessed at https://pubmed.ncbi.nlm.nih.gov/26724936/.


Hashtag: #CKLifeSciences #CancerVaccines #R&D

The issuer is solely responsible for the content of this announcement.

CK Life Sciences Int'l., (Holdings) Inc.

CK Life Sciences Int'l., (Holdings) Inc. (stock code: 0775) is listed on the Stock Exchange of Hong Kong. Bearing the mission of improving the quality of life, CK Life Sciences is engaged in the business of research and development, manufacturing, commercialisation, marketing, sale of, and investment in, products and assets which fall into three core categories - nutraceuticals, pharmaceuticals and agriculture-related. CK Life Sciences is a member of the CK Hutchison Group. For additional information, please visit .

About PRAME

PRAME is a protein commonly expressed by cancer cells, including melanoma (1), liver cancer (2), lung cancer (3) and breast cancer (4). PRAME contributes to the development and spread of cancer cells, and studies have shown that high levels of PRAME are associated with poor outcomes in cancer patients (2,4). In recent years, researchers have been exploring ways to target PRAME using immunotherapy, such as T-cell therapy and cancer vaccines, as a potential treatment for cancer.

About PD-L1

PD-L1 is a protein expressed by certain immune cells and cancer cells. It plays a role in suppressing anti-cancer immune responses by binding to a receptor called programmed death-1 (PD-1) on T-cells, limiting the activation of T-cells, thereby helping cancer cells evade the immune system. Antibodies that can block the interaction of PD-L1 and PD-1 have been approved for the treatment of certain types of cancer. Recent studies have shown the presence of PD-L1-specific T-cells in both healthy individuals and cancer patients, which suggests that targeting PD-L1 with T-cell therapy or cancer vaccines could be a promising approach for cancer treatment (5).

The Times Features

Riding in Style: Must-Have Bogs Gumboots for Equestrians

Key Highlights Bogs Gumboots offer superior comfort, durability, and waterproof protection, making them ideal for the demanding conditions of equestrian life. Their contoured...

How to Tell If You Need a New Roof in Melbourne Due to Leaks

Picture waking up in the early hours of the morning to the sound of mellow drips at your home, heralding the tremendous downpour of the previous night. As you look above, you not...

Rise of the Grey WoMad: Older Women Travelling Solo

Older Australian women are increasingly ditching their families and choosing to travel solo creating a new type of traveller known as the ‘Grey WoMad’. Budget travel platform ...

Why You Need an Expert Electrician for Your Business’s Electrical Upgrades and Repairs

When it comes to maintaining and upgrading your business’s electrical systems, it’s essential to call in a professional. Electrical work in any commercial setting requires the ex...

Why Is It Crucial to Have a Building Inspection Done Before Buying a New Home?

Purchasing a new property is a big financial decision that can impact your future for years. Whether you are a first-time buyer or an investor, good or bad, it is essential to en...

Online Application for Sick Leave Certificate: Understanding When and How to Secure One

A sick leave certificate is an official document issued by a healthcare professional to verify an individual's inability to attend work due to illness. It typically includes the ...

Times Magazine

The Ultimate Guide to Apple Watch Faces & Trending Wallpapers

In today’s digital world, personalization is everything. Your smartwatch isn’t just a timepiece—it’s an extension of your style. Thanks to innovative third-party developers, customizing your Apple Watch has reached new heights with stunning designs...

The Power of Digital Signage in Modern Marketing

In a fast-paced digital world, businesses must find innovative ways to capture consumer attention. Digital signage has emerged as a powerful solution, offering dynamic and engaging content that attracts and retains customers. From retail stores to ...

Why Cloud Computing Is the Future of IT Infrastructure for Enterprises

Globally, cloud computing is changing the way business organizations manage their IT infrastructure. It offers cheap, flexible and scalable solutions. Cloud technologies are applied in organizations to facilitate procedures and optimize operation...

First Nations Writers Festival

The First Nations Writers Festival (FNWF) is back for its highly anticipated 2025 edition, continuing its mission to celebrate the voices, cultures and traditions of First Nations communities through literature, art and storytelling. Set to take ...

Improving Website Performance with a Cloud VPS

Websites represent the new mantra of success. One slow website may make escape for visitors along with income too. Therefore it's an extra offer to businesses seeking better performance with more scalability and, thus represents an added attracti...

Why You Should Choose Digital Printing for Your Next Project

In the rapidly evolving world of print media, digital printing has emerged as a cornerstone technology that revolutionises how businesses and creative professionals produce printed materials. Offering unparalleled flexibility, speed, and quality, d...

LayBy Shopping